GlassScriptPhysician profile
Henry John Schulte, III
NPI 1114061553
$77,268.18
in general payments reported to CMS, 2019-2025
29 companies · $3,756 in 2025
The $3,756 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $11K · 2021: $5,068 · 2022: $8,100 · 2023: $9,911 · 2024: $9,741 · 2025: $3,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $4,700 · Travel and Lodging: $411 · Education: $72.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,225.00 |
| Food and Beverage | $4,699.86 |
| Travel and Lodging | $411.04 |
| Education | $72.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29,910.99 | 2019-2020 | |
| Abbvie INC. | $27,985.37 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $8,662.30 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Brainsway USA INC | $4,413.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $1,237.06 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $902.84 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $568.72 | 2019-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $543.22 | 2019-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $501.92 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $426.91 | 2020-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $421.21 | 2019-2025 | Rexulti |
| Corium, LLC | $412.85 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $285.06 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $187.14 | 2019-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $96.44 | 2023-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $95.13 | 2023-2024 | Ingrezza |
| Noven Therapeutics, LLC | $86.86 | 2020-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $86.64 | 2019-2023 | Aplenzin, Wellbutrin |
| Shire North American Group INC | $78.40 | 2019 | |
| Janssen Scientific Affairs, LLC | $72.40 | 2022 | |
| Eisai INC. | $63.94 | 2021 | |
| Almatica Pharma LLC | $62.61 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Alfasigma USA, INC. | $43.81 | 2020-2021 | |
| Tris Pharma INC | $23.46 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $21.65 | 2020 | |
| Owp Pharmaceuticals, INC. | $20.76 | 2021 | |
| Neuronetics, INC. | $20.67 | 2021 | |
| Supernus Pharmaceuticals, INC. | $20.36 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Schulte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.